Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical ...

GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing ...

CureVac (CVAC) has released an update. CureVac has appointed Axel Sven Malkomes as their new Chief Financial Officer, marking a strategic move as the company aims to accelerate its growth and ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TÜBINGEN, GERMANY and BOSTON, MA - CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA technology, today announced the appointment of Axel Sven Malkomes as its new Chief ...